Home PTC Therapeutics Receives Positive Opinion From CHMP For Translarna (ataluren)
 

Keywords :   


PTC Therapeutics Receives Positive Opinion From CHMP For Translarna (ataluren)

2014-06-04 13:02:23| drugdiscoveryonline News Articles

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older

Tags: positive opinion receives therapeutics

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11
24.113DSLL
24.11
24.11
24.11
24.11logicool flight switch panel
24.11Z
24.11 126
More »